Our Products

Help Shape Patient Care Worldwide

As a leading innovation-driven organisation, Lilly is developing a growing portfolio of pharmaceutical products focused on meeting some of the world's most urgent medical needs in the fields of Cardiovascular, Diabetes, Men's health, Musculoskeletal, Neuroscience and Oncology.

New Zealand laws and regulations limit the amount of product information that we can provide to the general public via our website. We encourage patients wishing to obtain more detailed information on our products to speak to their healthcare professional.

The product information on this website is intended for New Zealand residents.


Cardiovascular Patients Healthcare Providers
Effient® (prasugrel) CMI PI
Diabetes Patients Healthcare Providers
Humalog® / Humalog® Mix25 / Humalog® Mix50 (insulin lispro) CMI PI
Humulin® (biosynthetic human insulin) and Humulin® Vials CMI PI
Men's Health Patients Healthcare Providers
Cialis® (tadalafil) CMI PI
Musculoskeletal Patients Healthcare Providers
Evista® (raloxifene hydrochloride) CMI PI
Forteo® (teriparatide of recombinant DNA origin) CMI PI
Neuroscience Patients Healthcare Providers
Prozac® (fluoxetine hydrochloride) CMI PI
Strattera® (atomoxetine hydrochloride) CMI PI
Zyprexa® (olanzapine) - Tablets and Wafers CMI PI
Zyprexa® IM (olanzapine) - Injection CMI PI
Zyprexa® Relprevv (olanzapine) long acting injectable CMI PI
Oncology Patients Healthcare Providers
Alimta® (pemetrexed) PI PI